<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=129980757405201&amp;ev=PageView&amp;noscript=1">
  TRCcobrand_prl.png
The Role of PCSK9 Inhbitors

Complimentary On-Demand Webinar
PCSK9 Inhibitors.jpg

 

 

Fill out the form to watch the webinar now

This TRC Hot Topic webinar features a discussion on when to consider a PCSK9 inhibitor for patients with cardiovascular disease. Our featured panelist is Dr. Karol Watson, Co-director at UCLA’s Program in Preventive Cardiology. Dr. Watson, our TRC editors, and frontline providers will give their perspective on:

  • Do PCSK9 inhibitors improve CV outcomes?
  • How does the CV impact of ezetimibe compare with PCSK9 inhibitors?
  • Is adding a PCSK9 inhibitor more effective than adding ezetimibe to a statin?
  • When should ezetimibe or a PCSK9 inhibitor be considered?
  • Are very low LDL levels safe?